190 related articles for article (PubMed ID: 37223910)
21. Antiproliferative potential of miR-33a in laryngeal cancer Hep-2 cells via targeting PIM1.
Karatas OF
Head Neck; 2018 Nov; 40(11):2455-2461. PubMed ID: 30102806
[TBL] [Abstract][Full Text] [Related]
22. Long non-coding RNA LINC01003 suppresses the development of multiple myeloma by targeting miR-33a-5p/PIM1 axis.
Wu L; Xia L; Chen X; Ruan M; Li L; Xia R
Leuk Res; 2021 Jul; 106():106565. PubMed ID: 33865032
[TBL] [Abstract][Full Text] [Related]
23. Mechanistic basis and efficacy of targeting the β-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors.
Saenz DT; Fiskus W; Mill CP; Perera D; Manshouri T; Lara BH; Karkhanis V; Sharma S; Horrigan SK; Bose P; Kadia TM; Masarova L; DiNardo CD; Borthakur G; Khoury JD; Takahashi K; Bhaskara S; Lin CY; Green MR; Coarfa C; Crews CM; Verstovsek S; Bhalla KN
Blood; 2020 Apr; 135(15):1255-1269. PubMed ID: 32068780
[TBL] [Abstract][Full Text] [Related]
24. The combination of BET and PARP inhibitors is synergistic in models of cholangiocarcinoma.
Fehling SC; Miller AL; Garcia PL; Vance RB; Yoon KJ
Cancer Lett; 2020 Jan; 468():48-58. PubMed ID: 31605774
[TBL] [Abstract][Full Text] [Related]
25. Biological Effects of BET Inhibition by OTX015 (MK-8628) and JQ1 in NPM1-Mutated (NPM1c) Acute Myeloid Leukemia (AML).
Djamai H; Berrou J; Dupont M; Coudé MM; Delord M; Clappier E; Marceau-Renaut A; Kaci A; Raffoux E; Itzykson R; Berthier C; Wu HC; Hleihel R; Bazarbachi A; de Thé H; Baruchel A; Gardin C; Dombret H; Braun T
Biomedicines; 2021 Nov; 9(11):. PubMed ID: 34829934
[TBL] [Abstract][Full Text] [Related]
26. Vitamin C supplementation expands the therapeutic window of BETi for triple negative breast cancer.
Mustafi S; Camarena V; Qureshi R; Yoon H; Volmar CH; Huff TC; Sant DW; Zheng L; Brothers SP; Wahlestedt C; Slingerland J; Wang G
EBioMedicine; 2019 May; 43():201-210. PubMed ID: 30975544
[TBL] [Abstract][Full Text] [Related]
27. Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
Koblish H; Li YL; Shin N; Hall L; Wang Q; Wang K; Covington M; Marando C; Bowman K; Boer J; Burke K; Wynn R; Margulis A; Reuther GW; Lambert QT; Dostalik Roman V; Zhang K; Feng H; Xue CB; Diamond S; Hollis G; Yeleswaram S; Yao W; Huber R; Vaddi K; Scherle P
PLoS One; 2018; 13(6):e0199108. PubMed ID: 29927999
[TBL] [Abstract][Full Text] [Related]
28. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset.
Padi SKR; Luevano LA; An N; Pandey R; Singh N; Song JH; Aster JC; Yu XZ; Mehrotra S; Kraft AS
Oncotarget; 2017 May; 8(18):30199-30216. PubMed ID: 28415816
[TBL] [Abstract][Full Text] [Related]
29. BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression.
Tancredi A; Gusyatiner O; Bady P; Buri MC; Lomazzi R; Chiesi D; Messerer M; Hegi ME
Cell Death Dis; 2022 Dec; 13(12):1037. PubMed ID: 36513631
[TBL] [Abstract][Full Text] [Related]
30. Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling.
Brunen D; García-Barchino MJ; Malani D; Jagalur Basheer N; Lieftink C; Beijersbergen RL; Murumägi A; Porkka K; Wolf M; Zwaan CM; Fornerod M; Kallioniemi O; Martínez-Climent JÁ; Bernards R
Oncotarget; 2016 Jun; 7(25):37407-37419. PubMed ID: 27270648
[TBL] [Abstract][Full Text] [Related]
31. Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response.
Conery AR; Centore RC; Spillane KL; Follmer NE; Bommi-Reddy A; Hatton C; Bryant BM; Greninger P; Amzallag A; Benes CH; Mertz JA; Sims RJ
Cancer Res; 2016 Mar; 76(6):1313-9. PubMed ID: 26759243
[TBL] [Abstract][Full Text] [Related]
32. Concurrent targeting of MAP3K3 and BRD4 by
Liu C; Gen Y; Tanimoto K; Muramatsu T; Inoue J; Inazawa J
Mol Ther Nucleic Acids; 2021 Sep; 25():83-92. PubMed ID: 34258104
[TBL] [Abstract][Full Text] [Related]
33. Micro-RNA-125a mediates the effects of hypomethylating agents in chronic myelomonocytic leukemia.
Berg JL; Perfler B; Hatzl S; Mayer MC; Wurm S; Uhl B; Reinisch A; Klymiuk I; Tierling S; Pregartner G; Bachmaier G; Berghold A; Geissler K; Pichler M; Hoefler G; Strobl H; Wölfler A; Sill H; Zebisch A
Clin Epigenetics; 2021 Jan; 13(1):1. PubMed ID: 33407852
[TBL] [Abstract][Full Text] [Related]
34. Treatment advances for pediatric and adult onset neoplasms with monocytosis.
McCullough KB; Kuhn AK; Patnaik MM
Curr Hematol Malig Rep; 2021 Jun; 16(3):256-266. PubMed ID: 33728588
[TBL] [Abstract][Full Text] [Related]
35. ATF2 inhibits ani-tumor effects of BET inhibitor in a negative feedback manner by attenuating ferroptosis.
Wang L; Chen Y; Mi Y; Qiao J; Jin H; Li J; Lu Z; Wang Q; Zou Z
Biochem Biophys Res Commun; 2021 Jun; 558():216-223. PubMed ID: 33008584
[TBL] [Abstract][Full Text] [Related]
36. Monocytic differentiation and AHR signaling as Primary Nodes of BET Inhibitor Response in Acute Myeloid Leukemia.
Romine KA; Nechiporuk T; Bottomly D; Jeng S; McWeeney SK; Kaempf A; Corces MR; Majeti R; Tyner JW
Blood Cancer Discov; 2021 Sep; 2(5):518-531. PubMed ID: 34568834
[TBL] [Abstract][Full Text] [Related]
37. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1).
Decker S; Finter J; Forde AJ; Kissel S; Schwaller J; Mack TS; Kuhn A; Gray N; Follo M; Jumaa H; Burger M; Zirlik K; Pfeifer D; Miduturu CV; Eibel H; Veelken H; Dierks C
Mol Cancer Ther; 2014 May; 13(5):1231-45. PubMed ID: 24659821
[TBL] [Abstract][Full Text] [Related]
38. TNKS inhibitors potentiate proliferative inhibition of BET inhibitors via reducing β-Catenin in colorectal cancer cells.
Wu Q; Xuan YF; Su AL; Bao XB; Miao ZH; Wang YQ
Am J Cancer Res; 2022; 12(3):1069-1087. PubMed ID: 35411247
[TBL] [Abstract][Full Text] [Related]
39. Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents.
Casillas AL; Toth RK; Sainz AG; Singh N; Desai AA; Kraft AS; Warfel NA
Clin Cancer Res; 2018 Jan; 24(1):169-180. PubMed ID: 29084916
[No Abstract] [Full Text] [Related]
40. Specific Activation
Li G; Zhang Z; Reszka-Blanco N; Li F; Chi L; Ma J; Jeffrey J; Cheng L; Su L
J Virol; 2019 Jun; 93(12):. PubMed ID: 30971469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]